全球重症肌無力市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計重症肌無力市場規模將從 2025 年的 34 億美元成長到 2034 年的 78 億美元，並預計從 2026 年到 2034 年將以 9.67% 的複合年成長率成長。

隨著診斷、治療和疾病管理技術的進步，重症肌無力市場不斷擴大，患者預後也得到改善。這種自體免疫神經肌肉疾病需要採用精準的治療策略，包括乙醯膽鹼酯酶抑制劑、免疫抑制劑和單株抗體。盛行率的上升、公眾對疾病認知的提高以及獲得專業醫療服務的便利性改善，正在推動其在全球範圍內的蔓延。

科技創新正在改變我們治療疾病的方式。生物製藥、標靶治療和基因介入措施能夠改善症狀控制，提升患者的生活品質。人工智慧輔助診斷平台和穿戴式神經肌肉監測設備能夠實現即時評估、治療最佳化和遠端患者管理。與數位健康生態系統的整合使得個人化照護方案的發展和參與臨床試驗成為可能。

預計未來成長將主要得益於患者意識的提高、研究經費的增加以及新治療方法的引入。北美和歐洲憑藉其先進的醫療基礎設施，在應用方面處於主導，而亞太地區則正經歷意識提升和專科醫療中心的湧現。生物技術公司、製藥公司和醫療服務提供者之間的策略合作正在加速治療創新。重症肌無力治療方案可望在全球範圍內促進精準醫療、病患監測和臨床療效的提升。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球重症肌無力市場：依治療類型分類

• 市場分析、洞察與預測
• 膽鹼酯酶抑制劑
• 慢性免疫調節劑
• 單株抗體
• 快速免疫療法
• 胸腺切除術
• 其他

第5章：全球重症肌無力市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 其他

第6章 全球重症肌無力市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Alexion Pharmaceutical Inc
  • Grifols SA
  • Avadel Pharmaceuticals Plc. Novartis AG
  • Pfizer Inc
  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Bausch Health Companies Inc
  • Shire Plc

The Myasthenia Gravis Disease Market size is expected to reach USD 7.80 Billion in 2034 from USD 3.40 Billion (2025) growing at a CAGR of 9.67% during 2026-2034.

The myasthenia gravis market is expanding as advancements in diagnosis, therapeutics, and disease management improve patient outcomes. This autoimmune neuromuscular disorder requires precise treatment strategies involving acetylcholinesterase inhibitors, immunosuppressants, and monoclonal antibodies. Rising prevalence, better disease awareness, and improved access to specialized care are driving global adoption.

Technological innovation is reshaping care. Biologics, targeted therapies, and gene-based interventions enhance symptom management and patient quality of life. AI-assisted diagnostic platforms and wearable neuromuscular monitoring devices enable real-time assessment, treatment optimization, and remote patient management. Integration with digital health ecosystems allows personalized care plans and clinical trial participation.

Future growth is expected from rising patient awareness, research funding, and introduction of novel therapies. North America and Europe dominate adoption due to advanced healthcare infrastructure, while Asia-Pacific is witnessing growing awareness and specialized care centers. Strategic collaborations between biotech firms, pharmaceutical companies, and healthcare providers are accelerating therapeutic innovation. Myasthenia gravis treatment solutions are poised to improve precision care, patient monitoring, and clinical outcomes globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Cholinesterase Inhibitors
• Chronic Immunomodulators
• Monoclonal Antibodies
• Rapid Immunotherapies
• Thymectomy
• Others

By End-use

• Hospitals
• Clinics
• Others

COMPANIES PROFILED

• Alexion Pharmaceutical Inc, Grifols SA, Avadel Pharmaceuticals plc Novartis AG, Pfizer Inc, AbbVie Inc, F HoffmannLa Roche Ltd, GlaxoSmithKline plc, Bausch Health Companies Inc, Shire plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Cholinesterase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chronic Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Rapid Immunotherapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Thymectomy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Treatment Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Treatment Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Treatment Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Treatment Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Treatment Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MYASTHENIA GRAVIS DISEASE INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Alexion Pharmaceutical Inc
  • 8.2.2 Grifols SA
  • 8.2.3 Avadel Pharmaceuticals Plc. Novartis AG
  • 8.2.4 Pfizer Inc
  • 8.2.5 AbbVie Inc
  • 8.2.6 F. Hoffmann-La Roche Ltd
  • 8.2.7 GlaxoSmithKline Plc
  • 8.2.8 Bausch Health Companies Inc
  • 8.2.9 Shire Plc